Mental Health Clinics in New Haven, CT Accepting Medicare
188 Mental Health Clinics found. Showing 181 - 188
 Janice M Trelease, Lmft Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 773 Townsend Ave, New Haven, CT 06512 Phone: 203-824-5535 |
Stephen Advocate, Lcsw Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 281 Willow St, New Haven, CT 06511 Phone: 203-675-6615 |
Post Traumatic Stress Center Psychologist Medicare: Not Enrolled in Medicare Practice Location: 19 Edwards St, New Haven, CT 06511 Phone: 203-624-2146 Fax: 203-624-2791 |
Child Adult And Addiction Psychiatric Services Llc Psychiatry & Neurology - Addiction Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 123 York St, Suite 1-d, New Haven, CT 06511 Phone: 203-785-8655 Fax: 203-785-8422 |
Nina Gilbert Psychotherapy, Llc Clinic - Adult Mental Health Medicare: Not Enrolled in Medicare Practice Location: 79 Trumbull St Ste C9, New Haven, CT 06511 Phone: 203-535-1430 Fax: 475-202-6527 |
New Connection Inc Psychologist - Clinical Child & Adolescent Medicare: Not Enrolled in Medicare Practice Location: 446 Blake St # 200a, New Haven, CT 06515 Phone: 203-387-9400 |
Brenda's Way Counseling Services Pllc Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 157 Church St Fl 19, New Haven, CT 06510 Phone: 203-368-8538 |
The Connection Inc. Clinic - Adult Mental Health Medicare: Not Enrolled in Medicare Practice Location: 282 Dwight St, New Haven, CT 06511 Phone: 203-777-3216 Fax: 203-772-0705 |
News Archive
Exelixis announces regaining of rights to develop and commercialize XL184
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
Study results show no improvement in overall survival for combination of gemcitabine and Amplimexon
AmpliMed Corporation, a cancer therapeutics company, today announced results from AMP-019, a randomized double-blind, placebo-controlled Phase II screening trial designed to determine if a Phase III trial was warranted for the combination of gemcitabine (Gemzar, Eli Lilly) plus Amplimexon (AmpliMed Corporation) in patients with advanced pancreatic ductal adenocarcinoma of the pancreas.
First steps taken to treat human hereditary blindness
A team led by Krzysztof Palczewski, Ph.D., chair of pharmacology at the Case Western Reserve University School of Medicine, has taken the first steps in treating an eye disease causing irreversible congenital blindness in millions of people worldwide by successfully testing two new treatments in mice.
HSS presents research related to rheumatology and orthopedic surgery at 2020 ACR annual meeting
At this year's American College of Rheumatology virtual meeting, Hospital for Special Surgery (HSS) presented exciting research related to rheumatology and orthopedic surgery.
Research uncovers a new human sensory ability to detect sugars in the mouth
Most everyone understands that a major role of our sense of taste is to inform us when sugar is present in foods and beverages by eliciting sweetness on our tongues. A study led by the Monell Chemical Senses Center, published this month in PLOS ONE, identifies a new human sensory ability to detect sugars in the mouth with a molecular calorie detector, of sorts.
› Verified 1 days ago